Bazinaprine

Bazinaprine (SR-95,191) is an experimental drug candidate. It is a monoamine oxidase inhibitor (MAOI) which is believed to be useful for the treatment of depression. The drug strongly inhibits type A monoamine oxidase, but only weakly inhibits type B. The effects of the drug are reversible in vivo, but not in vitro.^[1] In studies, the chemical has been shown to not interact in vivo with other neurotransmitter or drug receptor sites.^[2]

Bazinaprine

Clinical data
ATC code	None
Identifiers
IUPAC name 3-{[2-(morpholin-4-yl)ethyl]amino}-6-phenylpyridazine-4-carbonitrile
CAS Number	94011-82-2 N
PubChem CID	72119
ChemSpider	65096 Y
UNII	NU8Y4C529J
ChEMBL	ChEMBL150365 Y
CompTox Dashboard (EPA)	DTXSID70240219
Chemical and physical data
Formula	C17H19N5O
Molar mass	309.373 g·mol−1
3D model (JSmol)	Interactive image
SMILES N#Cc2cc(nnc2NCCN1CCOCC1)c3ccccc3
InChI InChI=1S/C17H19N5O/c18-13-15-12-16(14-4-2-1-3-5-14)20-21-17(15)19-6-7-22-8-10-23-11-9-22/h1-5,12H,6-11H2,(H,19,21) Y Key:KRNDIPHOJLIHRI-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

See also

• Reversible inhibitor of MAO-A (RIMA)

References

1. Kan JP, Steinberg R, Leclercq J, Worms P, Biziere K (April 1988). "Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro". Journal of Neurochemistry. 50 (4): 1137–44. doi:10.1111/j.1471-4159.1988.tb10584.x. PMID 3346672. S2CID 12521641.
2. Kan JP, Steinberg R, Mouget-Goniot C, Worms P, Bizière K (January 1987). "SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition". The Journal of Pharmacology and Experimental Therapeutics. 240 (1): 251–8. PMID 3100771.